Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd..
BACKGROUND: We sought to identify potentially modifiable in-hospital factors associated with global cognition, post-traumatic stress disorder (PTSD) symptoms, and depression symptoms at 12 months.
METHODS: This was a multi-center prospective cohort study in adult hospitalized patients with acute COVID-19. The following in-hospital factors were assessed: delirium; frequency of in-person and virtual visits by friends and family; and hydroxychloroquine, corticosteroid, and remdesivir administration. Twelve-month global cognition was characterized by the MOCA-Blind. Twelve-month PTSD and depression were characterized using the PTSD Checklist for the DSM-V and Hospital Anxiety Depression Scale, respectively.
FINDINGS: Two hundred three patients completed the 12-month follow-up assessments. Remdesivir use was associated with significantly higher cognition at 12 months based on the MOCA-Blind (adjusted odds ratio [aOR] = 1.98, 95% CI: 1.06, 3.70). Delirium was associated with worsening 12-month PTSD (aOR = 3.44, 95% CI: 1.89, 6.28) and depression (aOR = 2.18, 95% CI: 1.23, 3.84) symptoms. Multiple virtual visits per day during hospitalization was associated with lower 12-month depression symptoms compared to those with less than daily virtual visits (aOR = 0.40, 95% CI: 0.19, 0.85).
CONCLUSION: Potentially modifiable factors associated with better long-term outcomes included remdesivir use (associated with better cognitive function), avoidance of delirium (associated with less PTSD and depression symptoms), and increased virtual interactions with friends and family (associated with less depression symptoms).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 17(2023), 9 vom: 01. Sept., Seite e13197 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Jin H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Depression |
|---|
| Anmerkungen: |
Date Completed 28.09.2023 Date Revised 03.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/irv.13197 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362483981 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362483981 | ||
| 003 | DE-627 | ||
| 005 | 20231226091335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.13197 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362483981 | ||
| 035 | |a (NLM)37752063 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Jin H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2023 | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: We sought to identify potentially modifiable in-hospital factors associated with global cognition, post-traumatic stress disorder (PTSD) symptoms, and depression symptoms at 12 months | ||
| 520 | |a METHODS: This was a multi-center prospective cohort study in adult hospitalized patients with acute COVID-19. The following in-hospital factors were assessed: delirium; frequency of in-person and virtual visits by friends and family; and hydroxychloroquine, corticosteroid, and remdesivir administration. Twelve-month global cognition was characterized by the MOCA-Blind. Twelve-month PTSD and depression were characterized using the PTSD Checklist for the DSM-V and Hospital Anxiety Depression Scale, respectively | ||
| 520 | |a FINDINGS: Two hundred three patients completed the 12-month follow-up assessments. Remdesivir use was associated with significantly higher cognition at 12 months based on the MOCA-Blind (adjusted odds ratio [aOR] = 1.98, 95% CI: 1.06, 3.70). Delirium was associated with worsening 12-month PTSD (aOR = 3.44, 95% CI: 1.89, 6.28) and depression (aOR = 2.18, 95% CI: 1.23, 3.84) symptoms. Multiple virtual visits per day during hospitalization was associated with lower 12-month depression symptoms compared to those with less than daily virtual visits (aOR = 0.40, 95% CI: 0.19, 0.85) | ||
| 520 | |a CONCLUSION: Potentially modifiable factors associated with better long-term outcomes included remdesivir use (associated with better cognitive function), avoidance of delirium (associated with less PTSD and depression symptoms), and increased virtual interactions with friends and family (associated with less depression symptoms) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a depression | |
| 650 | 4 | |a long-COVID | |
| 650 | 4 | |a long-term cognitive impairment | |
| 650 | 4 | |a modifiable risk factors | |
| 650 | 4 | |a post-traumatic stress disorder | |
| 700 | 1 | |a Jackson, James C |e verfasserin |4 aut | |
| 700 | 1 | |a Orun, Onur M |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Samuel M |e verfasserin |4 aut | |
| 700 | 1 | |a Casey, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Sean P |e verfasserin |4 aut | |
| 700 | 1 | |a Cordero, Kemberlyne |e verfasserin |4 aut | |
| 700 | 1 | |a Ginde, Adit A |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Michelle N |e verfasserin |4 aut | |
| 700 | 1 | |a Hough, Catherine L |e verfasserin |4 aut | |
| 700 | 1 | |a Iwashyna, Theodore J |e verfasserin |4 aut | |
| 700 | 1 | |a Kiehl, Amy L |e verfasserin |4 aut | |
| 700 | 1 | |a Lauck, Alana |e verfasserin |4 aut | |
| 700 | 1 | |a Leither, Lindsay M |e verfasserin |4 aut | |
| 700 | 1 | |a Lindsell, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Mayur B |e verfasserin |4 aut | |
| 700 | 1 | |a Raman, Rameela |e verfasserin |4 aut | |
| 700 | 1 | |a Rice, Todd W |e verfasserin |4 aut | |
| 700 | 1 | |a Ringwood, Nancy J |e verfasserin |4 aut | |
| 700 | 1 | |a Sheppard, Karen L |e verfasserin |4 aut | |
| 700 | 1 | |a Semler, Matthew W |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, B Taylor |e verfasserin |4 aut | |
| 700 | 1 | |a Ely, E Wesley |e verfasserin |4 aut | |
| 700 | 1 | |a Self, Wesley H |e verfasserin |4 aut | |
| 700 | 0 | |a National Heart, Lung, and Blood Institute PETAL Clinical Trials Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 17(2023), 9 vom: 01. Sept., Seite e13197 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:e13197 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.13197 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 9 |b 01 |c 09 |h e13197 | ||